These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

650 related items for PubMed ID: 29234914

  • 1. Discriminating MGMT promoter methylation status in patients with glioblastoma employing amide proton transfer-weighted MRI metrics.
    Jiang S, Rui Q, Wang Y, Heo HY, Zou T, Yu H, Zhang Y, Wang X, Du Y, Wen X, Chen F, Wang J, Eberhart CG, Zhou J, Wen Z.
    Eur Radiol; 2018 May; 28(5):2115-2123. PubMed ID: 29234914
    [Abstract] [Full Text] [Related]

  • 2. Structural and advanced imaging in predicting MGMT promoter methylation of primary glioblastoma: a region of interest based analysis.
    Han Y, Yan LF, Wang XB, Sun YZ, Zhang X, Liu ZC, Nan HY, Hu YC, Yang Y, Zhang J, Yu Y, Sun Q, Tian Q, Hu B, Xiao G, Wang W, Cui GB.
    BMC Cancer; 2018 Feb 21; 18(1):215. PubMed ID: 29467012
    [Abstract] [Full Text] [Related]

  • 3. Predicting O6-Methylguanine-DNA Methyltransferase Protein Expression in Primary Low- and High-Grade Gliomas Using Certain Qualitative Characteristics of Amide Proton Transfer-Weighted Magnetic Resonance Imaging.
    Su L, Gao P, Lin S, Wu B, Qin W, Lin Y, Xue J.
    World Neurosurg; 2018 Aug 21; 116():e814-e823. PubMed ID: 29803064
    [Abstract] [Full Text] [Related]

  • 4. An analysis of image texture, tumor location, and MGMT promoter methylation in glioblastoma using magnetic resonance imaging.
    Drabycz S, Roldán G, de Robles P, Adler D, McIntyre JB, Magliocco AM, Cairncross JG, Mitchell JR.
    Neuroimage; 2010 Jan 15; 49(2):1398-405. PubMed ID: 19796694
    [Abstract] [Full Text] [Related]

  • 5. Different diagnostic values of imaging parameters to predict pseudoprogression in glioblastoma subgroups stratified by MGMT promoter methylation.
    Yoon RG, Kim HS, Paik W, Shim WH, Kim SJ, Kim JH.
    Eur Radiol; 2017 Jan 15; 27(1):255-266. PubMed ID: 27048531
    [Abstract] [Full Text] [Related]

  • 6. Defining optimal cutoff value of MGMT promoter methylation by ROC analysis for clinical setting in glioblastoma patients.
    Yuan G, Niu L, Zhang Y, Wang X, Ma K, Yin H, Dai J, Zhou W, Pan Y.
    J Neurooncol; 2017 May 15; 133(1):193-201. PubMed ID: 28516344
    [Abstract] [Full Text] [Related]

  • 7. MGMT promoter methylation status as a prognostic factor for the outcome of gamma knife radiosurgery for recurrent glioblastoma.
    Kim BS, Kong DS, Seol HJ, Nam DH, Lee JI.
    J Neurooncol; 2017 Jul 15; 133(3):615-622. PubMed ID: 28536992
    [Abstract] [Full Text] [Related]

  • 8. MGMT Promoter Methylation Status in Initial and Recurrent Glioblastoma: Correlation Study with DWI and DSC PWI Features.
    Choi HJ, Choi SH, You SH, Yoo RE, Kang KM, Yun TJ, Kim JH, Sohn CH, Park CK, Park SH.
    AJNR Am J Neuroradiol; 2021 May 15; 42(5):853-860. PubMed ID: 33632732
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The TERT promoter mutation status and MGMT promoter methylation status, combined with dichotomized MRI-derived and clinical features, predict adult primary glioblastoma survival.
    Shu C, Wang Q, Yan X, Wang J.
    Cancer Med; 2018 Aug 15; 7(8):3704-3712. PubMed ID: 29984907
    [Abstract] [Full Text] [Related]

  • 12. Predicting MGMT Promoter Methylation of Glioblastoma from Dynamic Susceptibility Contrast Perfusion: A Radiomic Approach.
    Crisi G, Filice S.
    J Neuroimaging; 2020 Jul 15; 30(4):458-462. PubMed ID: 32374045
    [Abstract] [Full Text] [Related]

  • 13. Clinical correlation of MGMT protein expression and promoter methylation in Chinese glioblastoma patients.
    Tang K, Jin Q, Yan W, Zhang W, You G, Liu Y, Jiang T.
    Med Oncol; 2012 Jun 15; 29(2):1292-6. PubMed ID: 21394635
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Confounding factors in diagnostics of MGMT promoter methylation status in glioblastomas in stereotactic biopsies.
    Weise LM, Harter PN, Eibach S, Braczynski AK, Dunst M, Rieger J, Bähr O, Hattingen E, Steinbach JP, Plate KH, Seifert V, Mittelbronn M.
    Stereotact Funct Neurosurg; 2014 Jun 15; 92(3):129-39. PubMed ID: 24776650
    [Abstract] [Full Text] [Related]

  • 17. Fusion Radiomics Features from Conventional MRI Predict MGMT Promoter Methylation Status in Lower Grade Gliomas.
    Jiang C, Kong Z, Liu S, Feng S, Zhang Y, Zhu R, Chen W, Wang Y, Lyu Y, You H, Zhao D, Wang R, Wang Y, Ma W, Feng F.
    Eur J Radiol; 2019 Dec 15; 121():108714. PubMed ID: 31704598
    [Abstract] [Full Text] [Related]

  • 18. Multiregional radiomics features from multiparametric MRI for prediction of MGMT methylation status in glioblastoma multiforme: A multicentre study.
    Li ZC, Bai H, Sun Q, Li Q, Liu L, Zou Y, Chen Y, Liang C, Zheng H.
    Eur Radiol; 2018 Sep 15; 28(9):3640-3650. PubMed ID: 29564594
    [Abstract] [Full Text] [Related]

  • 19. Clinically Relevant Imaging Features for MGMT Promoter Methylation in Multiple Glioblastoma Studies: A Systematic Review and Meta-Analysis.
    Suh CH, Kim HS, Jung SC, Choi CG, Kim SJ.
    AJNR Am J Neuroradiol; 2018 Aug 15; 39(8):1439-1445. PubMed ID: 30002055
    [Abstract] [Full Text] [Related]

  • 20. Relationship between tumor enhancement, edema, IDH1 mutational status, MGMT promoter methylation, and survival in glioblastoma.
    Carrillo JA, Lai A, Nghiemphu PL, Kim HJ, Phillips HS, Kharbanda S, Moftakhar P, Lalaezari S, Yong W, Ellingson BM, Cloughesy TF, Pope WB.
    AJNR Am J Neuroradiol; 2012 Aug 15; 33(7):1349-55. PubMed ID: 22322613
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.